The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene

Oncogene

Volumn 30, Issue 25, 2011, Pages 2810-2822

  Zhang, X ^a,b   George, J ^a,b   Deb, S ^a   Degoutin, J L ^a,b   Takano, E A ^a   Fox, S B ^a   Bowtell, D D L ^a,b   Harvey, K F ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

clear cell cancer; Hippo pathway; oncogenic transformation; ovarian cancer; YAP

Indexed keywords

PROTEIN; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN;

ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DROSOPHILA MELANOGASTER; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MAMMAL; MUTATION; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; SALVADOR WARTS HIPPO PATHWAY; SIGNAL TRANSDUCTION; TISSUE GROWTH;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; FEMALE; HUMANS; NUCLEAR PROTEINS; ONCOGENES; OVARIAN NEOPLASMS; PACLITAXEL; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

DROSOPHILA MELANOGASTER; MAMMALIA;

EID: 79959658018     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.8     Document Type: Article

References (49)

1. Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R et al. (2007). YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 17: 2054-2060.
2. Chan SW, Lim CJ, Guo K, Ng CP, Lee I, Hunziker W et al. (2008). A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res 68: 2592-2598.
3. Chen L, Chan SW, Zhang X, Walsh M, Lim CJ, Hong W et al. (2010). Structural basis of YAP recognition by TEAD4 in the hippo pathway. Genes Dev 24: 290-300.
4. Chosdol K, Misra A, Puri S, Srivastava T, Chattopadhyay P, Sarkar C et al. (2009). Frequent loss of heterozygosity and altered expression of the candidate tumor suppressor gene 0FAT0 in human astrocytic tumors. BMC Cancer 9: 5.
5. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A et al. (2010). Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463: 360-363.
6. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA et al. (2007). Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 130: 1120-1133.
7. Fernandez LA, Northcott PA, Dalton J, Fraga C, Ellison D, Angers S et al. (2009). YAP1 is amplified and up-regulated in hedgehogassociated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes Dev 23: 2729-2741.
8. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G et al. (2007). Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158.
9. Grusche FA, Richardson HE, Harvey KF. (2010). Upstream regulation of the hippo size control pathway. Curr Biol 20: R574-R582.
10. Hao Y, Chun A, Cheung K, Rashidi B, Yang X. (2008). Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem 283: 5496-5509.
11. Harvey K, Tapon N. (2007). The Salvador-Warts-Hippo pathway- an emerging tumour-suppressor network. Nat Rev Cancer 7: 182-191.
12. Harvey KF, Pfleger CM, Hariharan IK. (2003). The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell 114: 457-467.
13. Huang J, Wu S, Barrera J, Matthews K, Pan D. (2005). The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila homolog of YAP. Cell 122: 421-434.
14. Ihaka R, Gentleman R. (1996). R: A language for data analysis and graphics. 5: 299-314.
15. Jia J, Zhang W, Wang B, Trinko R, Jiang J. (2003). The Drosophila Ste20 family kinase dMST functions as a tumor suppressor by restricting cell proliferation and promoting apoptosis. Genes Dev 17: 2514-2519.
16. Lai ZC, Wei X, Shimizu T, Ramos E, Rohrbaugh M, Nikolaidis N et al. (2005). Control of cell proliferation and apoptosis by mob as tumor suppressor, mats. Cell 120: 675-685.
17. Lee KP, Lee JH, Kim TS, Kim TH, Park HD, Byun JS et al. (2010). The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci USA 107: 8248-8253.
18. Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH et al. (2008). TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol 28: 2426-2436.
19. Li Z, Zhao B, Wang P, Chen F, Dong Z, Yang H et al. (2010). Structural insights into the YAP and TEAD complex. Genes Dev 24: 235-240.
20. Nakaya K, Yamagata HD, Arita N, Nakashiro KI, Nose M, Miki T et al. (2007). Identification of homozygous deletions of tumor suppressor gene FAT in oral cancer using CGH-array. Oncogene 26: 5300-5308.
21. Oka T, Mazack V, Sudol M. (2008). Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP). J Biol Chem 283: 27534-27546.
22. Ota M, Sasaki H. (2008). Mammalian tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling. Development 135: 4059-4069.
23. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC et al. (2006). Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA 103: 12405-12410.
24. Pantalacci S, Tapon N, Leopold P. (2003). The Salvador partner Hippo promotes apoptosis and cell-cycle exit in Drosophila. Nat Cell Biol 5: 921-927.
25. Qi C, Zhu YT, Hu L, Zhu YJ. (2009). Identification of Fat4 as a candidate tumor suppressor gene in breast cancers. Int J Cancer 124: 793-798.
26. Reiner A, Yekutieli D, Benjamini Y. (2003). Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 19: 368-375.
27. Smyth GK. (2004). Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article 3.
28. Smyth GK (ed.) (2005). Limma: Linear Models for Microarray Data. Springer, New York, pp 397-420.
29. St John MA, Tao W, Fei X, Fukumoto R, Carcangiu ML, Brownstein DG et al (1999). Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nat Genet 21: 182-186.
30. Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D et al. (2008). Expression of Yes-associated protein in common solid tumors. Hum Pathol 39: 1582-1589.
31. Stewart BW, Kleihues P (eds) (2003). World Cancer Report. IARC Press: Lyon.
32. Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, Tamaki Y et al. (2005). Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res 11: 1380-1385.
33. Tan DS, Kaye S. (2007). Ovarian clear cell adenocarcinoma: a continuing enigma. J Clin Pathol 60: 355-360.
34. Tapon N, Harvey KF, Bell DW, Wahrer DC, Schiripo TA, Haber DA et al. (2002). Salvador promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell 110: 467-478.
35. Tian W, Yu J, Tomchick DR, Pan D, Luo X. (2010). Structural and functional analysis of the YAP-binding domain of human TEAD2. Proc Natl Acad Sci USA 107: 7293-7298.
36. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S et al (2008). Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14: 5198-5208.
37. Udan RS, Kango-Singh M, Nolo R, Tao C, Halder G. (2003). Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway. Nat Cell Biol 5: 914-920.
38. WangY,DongQ,Zhang Q, Li Z, Wang E, QiuX. (2010). Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci 101: 1279-1285.
39. Wu S, Huang J, Dong J, Pan D. (2003). Hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell 114: 445-456.
40. Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L et al. (2009). Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 115: 4576-4585.
41. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J et al. (2006). Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125: 1253-1267.
42. Zeng Q, Hong W. (2008). The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. Cancer Cell 13: 188-192.
43. Zhang J, Smolen GA, Haber DA. (2008). Negative regulation of YAP by LATS1 underscores evolutionary conservation of the Drosophila Hippo pathway. Cancer Res 68: 2789-2794.
44. Zhang X, Ling MT, Wang X, Wong YC. (2006). Inactivation of Id-1 in prostate cancer cells: a potential therapeutic target in inducing chemosensitization to taxol through activation of JNK pathway. Int J Cancer 118: 2072-2081.
45. Zhang X, Milton CC, Humbert PO, Harvey KF. (2009). Transcriptional output of the Salvador/warts/hippo pathway is controlled in distinct fashions in Drosophila melanogaster and mammalian cell lines. Cancer Res 69: 6033-6041.
46. Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. (2010). A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev 24: 72-85.
47. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J et al. (2007). Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 21: 2747-2761.
48. Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y et al. (2009). Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 16: 425-438.
49. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ et al. (2005). Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 11: 6422-6430.